Literature DB >> 33536296

Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Sara L Revolinski1, Christopher D Doern2.   

Abstract

INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.
Copyright © 2021 American Society for Microbiology.

Entities:  

Year:  2021        PMID： 33536296      PMCID： PMC8092730          DOI： 10.1128/JCM.00239-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  53 in total

Review 1.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Authors:  Kristen M Gawronski; Debra A Goff; Jack Brown; Tina M Khadem; Karri A Bauer
Journal:  Clin Ther       Date:  2013-06       Impact factor: 3.393

4.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

5.  Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Authors:  D M Martirosov; M R Bidell; M P Pai; M H Scheetz; S L Rosenkranz; T P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2017-04-02       Impact factor: 2.803

6.  Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

Authors:  Thomas P Lodise; George L Drusano; Evan Zasowski; Amanda Dihmess; Victoria Lazariu; Leon Cosler; Louise-Anne McNutt
Journal:  Clin Infect Dis       Date:  2014-05-27       Impact factor: 9.079

7.  Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.

Authors:  Andrea Hahn; Robert W Frenck; Mary Allen-Staat; Yuanshu Zou; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2015-10       Impact factor: 3.681

8.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

9.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Authors:  In-Gyu Bae; Jerome J Federspiel; José M Miró; Christopher W Woods; Lawrence Park; Michael J Rybak; Thomas H Rude; Suzanne Bradley; Suzana Bukovski; Cristina Garcia de la Maria; Souha S Kanj; Tony M Korman; Francesc Marco; David R Murdoch; Patrick Plesiat; Marta Rodriguez-Creixems; Porl Reinbott; Lisa Steed; Pierre Tattevin; Marie-Françoise Tripodi; Karly L Newton; G Ralph Corey; Vance G Fowler
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

10.  Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus.

Authors:  Seenae Eum; Robert L Bergsbaken; Craig L Harvey; J Bryan Warren; John C Rotschafer
Journal:  Antibiotics (Basel)       Date:  2016-09-27
View more
  1 in total

1.  Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study.

Authors:  Sara Alosaimy; Abdalhamid M Lagnf; Taylor Morrisette; Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Marco R Scipione; Jing J Zhao; Ryan Mynatt; Shelbye Herbin; Sorabh Dhar; Teena Chopra; James Janisse; Nicholas Rebold; Jason M Pogue; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.